Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

C Vogelmeier, A D'Urzo, R Pauwels, J M Merino, M Jaspal, S Boutet, I Naya, D Price

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

This 12-month dose-titration study assessed the effectiveness of budesonide/formoterol for maintenance plus relief with a control group using salmeterol/fluticasone for maintenance plus salbutamol for relief.

Adolescents and adults (n=2,143; mean forced expiratory volume in one second (FEV1) 73% predicted; mean inhaled corticosteroid (ICS) 884 mu g center dot day(-1)) were randomised to budesonide/formoterol 160/4.5 mu g two inhalations b.i.d. plus additional inhalations as needed, or salmeterol/fluticasone 50/250 mu g b.i.d. plus salbutamol as needed. Treatment was prescribed open label; after 4 weeks, physicians could titrate maintenance doses in accordance with normal clinical practice.

Maintenance plus as-needed budesonide/formoterol prolonged the time to first severe exacerbation versus salmeterol/fluticasone (25% risk reduction). The total number of severe exacerbations was significantly reduced in the budesonide/formoterol group (255 versus 329). Both regimens provided sustained improvements in symptoms, as-needed use, quality of life and FEV1, with differences in favour of the budesonide/formoterol group for as-needed use (0.58 versus 0.93 inhalations-day(-1)) and FEV1 (post-beta(2)-agonist values). Mean ICS dose during treatment was similar in both groups (653 mu g budesonide center dot day(-1) (maintenance plus as-needed) versus 583 mu g fluticasone center dot day(-1)).

The simplified strategy using budesonide/formoterol for maintenance and reliever therapy is feasible, safe and at least as effective as salmeterol/fluticasone plus salbutamol.

Original languageEnglish
Pages (from-to)819-828
Number of pages10
JournalEuropean Respiratory Journal
Volume26
DOIs
Publication statusPublished - 2005

Keywords

  • asthma
  • budesonide/formoterol
  • salmeterol/fluticasone
  • Seretide (R)/Advair (R)
  • Symbicort (R)
  • OF-LIFE QUESTIONNAIRE
  • SINGLE INHALER
  • FLUTICASONE PROPIONATE
  • BUDESONIDE
  • FORMOTEROL
  • MODERATE
  • SALMETEROL
  • MEDICATION
  • SAFETY
  • BETA(2)-AGONIST

Cite this

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? / Vogelmeier, C ; D'Urzo, A ; Pauwels, R ; Merino, J M ; Jaspal, M ; Boutet, S ; Naya, I ; Price, D .

In: European Respiratory Journal, Vol. 26, 2005, p. 819-828.

Research output: Contribution to journalArticle

Vogelmeier, C ; D'Urzo, A ; Pauwels, R ; Merino, J M ; Jaspal, M ; Boutet, S ; Naya, I ; Price, D . / Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. In: European Respiratory Journal. 2005 ; Vol. 26. pp. 819-828.
@article{f25617f470164a56ae6905f213f0f971,
title = "Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?",
abstract = "This 12-month dose-titration study assessed the effectiveness of budesonide/formoterol for maintenance plus relief with a control group using salmeterol/fluticasone for maintenance plus salbutamol for relief.Adolescents and adults (n=2,143; mean forced expiratory volume in one second (FEV1) 73{\%} predicted; mean inhaled corticosteroid (ICS) 884 mu g center dot day(-1)) were randomised to budesonide/formoterol 160/4.5 mu g two inhalations b.i.d. plus additional inhalations as needed, or salmeterol/fluticasone 50/250 mu g b.i.d. plus salbutamol as needed. Treatment was prescribed open label; after 4 weeks, physicians could titrate maintenance doses in accordance with normal clinical practice.Maintenance plus as-needed budesonide/formoterol prolonged the time to first severe exacerbation versus salmeterol/fluticasone (25{\%} risk reduction). The total number of severe exacerbations was significantly reduced in the budesonide/formoterol group (255 versus 329). Both regimens provided sustained improvements in symptoms, as-needed use, quality of life and FEV1, with differences in favour of the budesonide/formoterol group for as-needed use (0.58 versus 0.93 inhalations-day(-1)) and FEV1 (post-beta(2)-agonist values). Mean ICS dose during treatment was similar in both groups (653 mu g budesonide center dot day(-1) (maintenance plus as-needed) versus 583 mu g fluticasone center dot day(-1)).The simplified strategy using budesonide/formoterol for maintenance and reliever therapy is feasible, safe and at least as effective as salmeterol/fluticasone plus salbutamol.",
keywords = "asthma, budesonide/formoterol, salmeterol/fluticasone, Seretide (R)/Advair (R), Symbicort (R), OF-LIFE QUESTIONNAIRE, SINGLE INHALER, FLUTICASONE PROPIONATE, BUDESONIDE, FORMOTEROL, MODERATE, SALMETEROL, MEDICATION, SAFETY, BETA(2)-AGONIST",
author = "C Vogelmeier and A D'Urzo and R Pauwels and Merino, {J M} and M Jaspal and S Boutet and I Naya and D Price",
year = "2005",
doi = "10.1183/09031936.05.00028305",
language = "English",
volume = "26",
pages = "819--828",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",

}

TY - JOUR

T1 - Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

AU - Vogelmeier, C

AU - D'Urzo, A

AU - Pauwels, R

AU - Merino, J M

AU - Jaspal, M

AU - Boutet, S

AU - Naya, I

AU - Price, D

PY - 2005

Y1 - 2005

N2 - This 12-month dose-titration study assessed the effectiveness of budesonide/formoterol for maintenance plus relief with a control group using salmeterol/fluticasone for maintenance plus salbutamol for relief.Adolescents and adults (n=2,143; mean forced expiratory volume in one second (FEV1) 73% predicted; mean inhaled corticosteroid (ICS) 884 mu g center dot day(-1)) were randomised to budesonide/formoterol 160/4.5 mu g two inhalations b.i.d. plus additional inhalations as needed, or salmeterol/fluticasone 50/250 mu g b.i.d. plus salbutamol as needed. Treatment was prescribed open label; after 4 weeks, physicians could titrate maintenance doses in accordance with normal clinical practice.Maintenance plus as-needed budesonide/formoterol prolonged the time to first severe exacerbation versus salmeterol/fluticasone (25% risk reduction). The total number of severe exacerbations was significantly reduced in the budesonide/formoterol group (255 versus 329). Both regimens provided sustained improvements in symptoms, as-needed use, quality of life and FEV1, with differences in favour of the budesonide/formoterol group for as-needed use (0.58 versus 0.93 inhalations-day(-1)) and FEV1 (post-beta(2)-agonist values). Mean ICS dose during treatment was similar in both groups (653 mu g budesonide center dot day(-1) (maintenance plus as-needed) versus 583 mu g fluticasone center dot day(-1)).The simplified strategy using budesonide/formoterol for maintenance and reliever therapy is feasible, safe and at least as effective as salmeterol/fluticasone plus salbutamol.

AB - This 12-month dose-titration study assessed the effectiveness of budesonide/formoterol for maintenance plus relief with a control group using salmeterol/fluticasone for maintenance plus salbutamol for relief.Adolescents and adults (n=2,143; mean forced expiratory volume in one second (FEV1) 73% predicted; mean inhaled corticosteroid (ICS) 884 mu g center dot day(-1)) were randomised to budesonide/formoterol 160/4.5 mu g two inhalations b.i.d. plus additional inhalations as needed, or salmeterol/fluticasone 50/250 mu g b.i.d. plus salbutamol as needed. Treatment was prescribed open label; after 4 weeks, physicians could titrate maintenance doses in accordance with normal clinical practice.Maintenance plus as-needed budesonide/formoterol prolonged the time to first severe exacerbation versus salmeterol/fluticasone (25% risk reduction). The total number of severe exacerbations was significantly reduced in the budesonide/formoterol group (255 versus 329). Both regimens provided sustained improvements in symptoms, as-needed use, quality of life and FEV1, with differences in favour of the budesonide/formoterol group for as-needed use (0.58 versus 0.93 inhalations-day(-1)) and FEV1 (post-beta(2)-agonist values). Mean ICS dose during treatment was similar in both groups (653 mu g budesonide center dot day(-1) (maintenance plus as-needed) versus 583 mu g fluticasone center dot day(-1)).The simplified strategy using budesonide/formoterol for maintenance and reliever therapy is feasible, safe and at least as effective as salmeterol/fluticasone plus salbutamol.

KW - asthma

KW - budesonide/formoterol

KW - salmeterol/fluticasone

KW - Seretide (R)/Advair (R)

KW - Symbicort (R)

KW - OF-LIFE QUESTIONNAIRE

KW - SINGLE INHALER

KW - FLUTICASONE PROPIONATE

KW - BUDESONIDE

KW - FORMOTEROL

KW - MODERATE

KW - SALMETEROL

KW - MEDICATION

KW - SAFETY

KW - BETA(2)-AGONIST

U2 - 10.1183/09031936.05.00028305

DO - 10.1183/09031936.05.00028305

M3 - Article

VL - 26

SP - 819

EP - 828

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

ER -